Related Experiment Video

Updated: Mar 28, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Frailty Syndrome in Heart Failure Patients who are Receiving Cardiac Resynchronization

Agnieszka Mlynarska1,2, Rafal Mlynarski2, Jolanta Biernat2

  • 1Department of Internal Nursing, Chair of Internal Medicine, School of Health Sciences, Medical University of Silesia, Katowice, Poland.

Pacing and Clinical Electrophysiology : PACE
|December 19, 2015
PubMed

Insights

Patients undergoing new cardiac resynchronization therapy (CRT) implantation show greater frailty. This highlights the importance of assessing frailty in older heart failure patients receiving CRT.

Area of Science:

  • Cardiology
  • Geriatrics
  • Clinical Medicine

Background:

  • Frailty is a significant concern in elderly patients with heart failure.
  • Cardiac resynchronization therapy (CRT) is a treatment option for heart failure.
  • The frailty status of patients undergoing de novo CRT versus CRT upgrades is not well understood.

Purpose of the Study:

  • To compare the intensity of frailty syndrome in elderly patients receiving de novo CRT implantation versus those undergoing an upgrade from standard right heart pacing.

Main Methods:

  • A cohort of 106 patients aged 65 years or older were analyzed.
  • Patients were divided into two groups: de novo CRT implantation (n=74) and upgrade from right heart pacing (n=32).
  • Frailty was assessed using the Canadian Study of Health and Aging Clinical Frailty Scale (CSHA-CFS).

Main Results:

  • De novo CRT patients exhibited statistically higher CSHA-CFS scores (5.3 ± 0.8) compared to upgrade patients (4.9 ± 0.8; P = 0.027).
  • Frailty syndrome was identified in 81.1% of de novo patients versus 68.7% of upgrade patients (P = 0.164).
  • Nearly all patients (105/106) displayed some degree of frailty.

Conclusions:

  • Frailty syndrome is highly prevalent in heart failure patients over 65.
  • Patients receiving de novo CRT implantation are more likely to have significant frailty.
  • Frailty assessment is crucial for older heart failure patients considered for CRT.
Abstract

Keywords:
cardiac resynchronization therapycardioverter defibrillatorfrailtyheart failurepacemaker

More Related Videos

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.6K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.2K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
547
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
846
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K